List of Excipients in Branded Drug MAVYRET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	MAVYRET	glecaprevir and pibrentasvir	0074-2625	COPOVIDONE K25-31	2032-11-18
AbbVie Inc	MAVYRET	glecaprevir and pibrentasvir	0074-2625	CROSCARMELLOSE SODIUM	2032-11-18
AbbVie Inc	MAVYRET	glecaprevir and pibrentasvir	0074-2625	FERRIC OXIDE RED	2032-11-18
AbbVie Inc	MAVYRET	glecaprevir and pibrentasvir	0074-2625	HYPROMELLOSE 2910	2032-11-18
AbbVie Inc	MAVYRET	glecaprevir and pibrentasvir	0074-2625	LACTOSE MONOHYDRATE	2032-11-18

Mavyret Excipient Strategy and Commercial Opportunities

Last updated: September 3, 2026

Mavyret combines the HCV antivirals glecaprevir and pibrentasvir in a fixed-dose oral product. Its excipient strategy is built around solubility enhancement, powder processing, rapid disintegration, film protection, and pediatric dose flexibility. The commercial opportunity is strongest in qualified excipient supply, pediatric multiparticulate delivery, generic formulation development, analytical services, and contract manufacturing.

Mavyret is marketed by AbbVie as film-coated tablets and oral pellets. The tablet delivers 100 mg of glecaprevir and 40 mg of pibrentasvir. The standard adult regimen is three tablets once daily, providing 300 mg of glecaprevir and 120 mg of pibrentasvir, typically for eight weeks in treatment-naive patients without cirrhosis or with compensated cirrhosis, subject to genotype and clinical factors [1].

What excipients are used in Mavyret tablets?

Mavyret tablets use a combination of functional excipients associated with poorly soluble small molecules and high drug loading. The U.S. prescribing information identifies the following inactive ingredients [1]:

Excipient	Primary formulation role
Copovidone	Binder, solubility and dispersion aid
Vitamin E polyethylene glycol succinate, or vitamin E TPGS	Surfactant and solubilizer
Colloidal silicon dioxide	Glidant and moisture-flow control
Propylene glycol monolaurate, type II	Lipidic solubilizer and wetting agent
Croscarmellose sodium	Superdisintegrant
Sodium stearyl fumarate	Tablet lubricant
Hypromellose	Film-forming polymer
Lactose monohydrate	Film-coating or coating-bulk component
Titanium dioxide	Opacifier and color modifier
Iron oxides	Tablet-coating colorants

The composition indicates that AbbVie designed the product around performance rather than a simple direct-compression tablet. Vitamin E TPGS and propylene glycol monolaurate are particularly important because they can improve wetting and apparent solubility for hydrophobic drug substances. Copovidone supports granulation, binding, and drug dispersion. Croscarmellose sodium offsets the risk of slower tablet breakup caused by hydrophobic or lipidic materials.

How does Mavyret’s formulation improve solubility and bioavailability?

Mavyret’s active ingredients have different antiviral targets and physicochemical requirements. Glecaprevir is an HCV NS3/4A protease inhibitor, while pibrentasvir is an NS5A inhibitor. Both are highly potent, allowing a practical tablet dose, but the formulation must deliver reproducible exposure from compounds with limited aqueous solubility [1,2].

The excipient architecture supports four performance objectives:

1. Wetting of hydrophobic drug particles.
2. Dispersion of drug substance during manufacturing.
3. Rapid tablet disintegration after administration.
4. Consistent dissolution across fed and fasted conditions.

Vitamin E TPGS is commercially attractive because it combines surfactant behavior with solid-dose processing utility. It is commonly used to improve wetting and dissolution of poorly water-soluble compounds. Propylene glycol monolaurate provides a complementary lipidic function. The combination can create a more robust dissolution environment than a single surfactant.

Copovidone is also strategically important. It can function as a binder and can help maintain drug distribution in a solid matrix. Its use may reduce segregation risk when the active ingredients and excipients have different particle sizes or densities.

The product’s food instructions also reflect formulation behavior. Mavyret may be taken with food, and the label does not require a particular fat content. That simplifies patient use compared with HCV products that have more restrictive food requirements [1].

What excipients are used in Mavyret oral pellets?

Mavyret oral pellets extend the product into pediatric treatment and patients who cannot reliably swallow tablets. The oral-pellet formulation contains the same active ingredients at lower unit strengths and uses a similar functional excipient strategy, including solubilizing, binding, disintegrating, flow-control, and coating components [3].

The pediatric formulation creates a different commercial and technical opportunity from the adult tablet:

Product format	Commercial purpose	Key technical requirement
Film-coated tablets	Adult and older pediatric treatment	High drug loading, rapid dissolution, swallowability
Oral pellets	Younger children and patients with swallowing difficulty	Dose flexibility, content uniformity, mouthfeel, stability
Sachet presentation	Unit-dose pediatric administration	Moisture protection, low-dose accuracy, packaging compatibility

The pellet format is not a simple smaller tablet. Multiparticulate products require tight control of pellet size distribution, active loading, segregation, coating uniformity, sachet fill accuracy, and dose recovery from food or liquid vehicles. Suppliers with experience in fluid-bed coating, hot-melt or lipid processing, and low-dose multiparticulate manufacturing are better positioned than commodity excipient distributors.

What commercial opportunities exist for Mavyret excipient suppliers?

The largest opportunity is not the sale of a single excipient. It is the supply of a validated excipient system with regulatory documentation and manufacturing consistency.

Vitamin E TPGS and lipidic solubilizers

Vitamin E TPGS suppliers can compete on:

• Pharmaceutical-grade consistency.
• Low peroxide and impurity profiles.
• Particle-size control.
• Flow and melting behavior.
• Global regulatory documentation.
• Security of supply.

Propylene glycol monolaurate type II creates a narrower opportunity. Suppliers must support the required chemical grade, impurity profile, microbial controls, and batch-to-batch functionality. A manufacturer that can qualify both TPGS and lipidic co-solubilizers may offer a more valuable development package than a single-ingredient supplier.

Copovidone and co-processed systems

Copovidone suppliers can position products for immediate-release solid dispersions, granulation, and high-load tablets. The commercial value increases when the supplier provides:

• Grade-selection data.
• Viscosity and molecular-weight characterization.
• Moisture and peroxide specifications.
• Compatibility studies with lipidic excipients.
• Dissolution data using relevant HCV drug-substance models.

Co-processed binder-solubilizer systems could reduce development time for generic or reformulated products, although a generic manufacturer must still establish equivalence to the reference product.

Croscarmellose sodium and tablet-performance excipients

Croscarmellose sodium is a mature excipient category, but performance differences can affect disintegration and dissolution. Suppliers can compete through controlled swelling, low fibrous variability, low microbial burden, and better tablet robustness at lower use levels.

Sodium stearyl fumarate is also relevant because it can provide lubrication with less hydrophobic impact than some conventional lubricants. A supplier that supports low-level lubrication without compromising dissolution can target high-performance immediate-release products.

How strong is the formulation protection for Mavyret?

Mavyret is protected through a combination of active-ingredient patents, fixed-dose combination claims, pharmaceutical-composition claims, methods of treatment, and potentially manufacturing or solid-form claims. The relevant patent estate is distinct from the excipient list in the FDA label.

The commercial importance of the excipients is therefore twofold:

1. They may help reproduce the reference product’s dissolution and bioavailability.
2. They may create formulation-development constraints without necessarily being patent-protected themselves.

FDA Orange Book listings should be reviewed for the current patent numbers, expiration dates, and any pediatric exclusivity extensions associated with Mavyret [4]. A formulation that copies the functional architecture of the reference product can still require a separate patent-freedom-to-operate analysis, particularly where claims cover combinations of glecaprevir, pibrentasvir, solubilizers, solid dispersions, particle engineering, or dosage forms.

Excipient identity alone does not establish infringement. Patent risk depends on claim language, prosecution history, jurisdiction, and whether the generic formulation practices each required limitation.

When does Mavyret lose exclusivity and what generic entry risks exist?

Mavyret is a small-molecule product, not a biologic. Biosimilar pathways do not apply. Potential competitors would generally pursue an abbreviated new drug application, subject to applicable patents, exclusivity, and FDA requirements.

Generic entry risk has four main components:

Risk category	Relevance to Mavyret
Active-ingredient patents	May delay approval or launch
Fixed-dose combination claims	Can constrain products containing both actives
Formulation and dissolution claims	May affect excipient selection and process design
Method-of-use claims	Can require a Paragraph IV strategy or carve-out

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The product has two active ingredients, multiple daily tablets, and a formulation that uses solubilizing excipients. That increases development complexity compared with a conventional single-API immediate-release tablet.

A generic manufacturer may pursue one of three strategies:

• Match the reference excipient architecture closely.
• Use a different excipient system that achieves equivalent dissolution and exposure.
• Develop an alternative dosage form, subject to separate regulatory and patent analysis.

The first strategy can reduce formulation risk but may increase freedom-to-operate concerns. The second may reduce patent exposure but requires stronger development evidence. The third may create a commercial niche, especially for pediatric or swallowing-impaired populations, but can move the product outside a straightforward generic substitution model.

What FDA regulatory issues affect Mavyret excipient commercialization?

FDA review of a generic or reformulated Mavyret product would focus on more than inactive-ingredient identity. Key issues include:

• Excipient safety at the proposed daily intake.
• Compliance with applicable FDA Inactive Ingredient Database precedents.
• Drug-excipient compatibility.
• Dissolution similarity for both active ingredients.
• Content uniformity across the combination product.
• Stability under long-term and accelerated conditions.
• Moisture and oxidation control for lipidic excipients.
• Manufacturing-process reproducibility.
• Packaging protection for pellets and tablets.
• Acceptability of flavor, mouthfeel, and administration vehicles for pediatric products.

The reference product’s excipients can be used as a development benchmark, but the generic product does not necessarily need to use identical inactive ingredients. The formulation must meet the applicable ANDA requirements and demonstrate equivalent performance [5].

Excipient suppliers can improve their commercial position by maintaining Drug Master File support, change-control documentation, residual-solvent data, elemental-impurity assessments, nitrosamine-risk evaluations where relevant, and global compendial compliance.

What manufacturing and intellectual-property barriers affect the market?

The main manufacturing barriers are process integration and control of the lipidic excipients. TPGS and propylene glycol monolaurate can influence blending, granulation, compression, tablet ejection, dissolution, and stability. Their behavior can vary with temperature, moisture, particle size, and storage history.

For oral pellets, the barriers are higher. Manufacturers must control:

• Drug loading per pellet.
• Pellet size and density.
• Coating uniformity.
• Segregation during sachet filling.
• Dose recovery from the administration medium.
• Moisture ingress during storage.
• Taste and mouthfeel.

These requirements favor CDMOs with multiparticulate capabilities and suppliers that can provide process-grade excipients rather than only catalog materials.

Geographic coverage also matters. Mavyret is marketed internationally, and suppliers may need regional compendial support, dual manufacturing sites, and consistent quality documentation across the United States, Europe, Japan, and other regulated markets. A supplier with only one qualified site may be commercially disadvantaged in a product exposed to global tendering and supply-chain scrutiny.

How does Mavyret compare with competing HCV drugs?

Mavyret has a broad genotype profile and an eight-week treatment option for many eligible patients. Its main commercial competition comes from other direct-acting antiviral combinations, including sofosbuvir/velpatasvir products and elbasvir/grazoprevir in narrower populations [1,6].

Product	Key actives	Formulation opportunity
Mavyret	Glecaprevir/pibrentasvir	Lipidic solubilization, tablet and pediatric pellets
Epclusa	Sofosbuvir/velpatasvir	Fixed-dose tablet, solubility and dissolution control
Zepatier	Elbasvir/grazoprevir	Fixed-dose tablet, formulation and combination-product development
Authorized and conventional generics	Varies	Cost reduction, regional access, alternative excipients

Mavyret’s pediatric pellet format gives it a differentiated excipient and delivery opportunity. A competing product would need to match clinical utility, dosing simplicity, administration convenience, and regulatory evidence rather than only tablet composition.

What licensing and partnership opportunities exist?

Potential partnership models include:

1. Excipient supply agreements with dual-source provisions.
2. Joint development of TPGS-lipidic solubilizer systems.
3. CDMO arrangements for pediatric pellets.
4. Generic formulation licensing after patent review.
5. Analytical-method transfer for dissolution and stability testing.
6. Regional commercialization of pediatric or alternative dosage forms.
7. Packaging partnerships for moisture-sensitive unit-dose products.

The strongest opportunities are likely to involve proprietary process knowledge, validated excipient grades, or pediatric delivery technology. Commodity supply of lactose, colloidal silicon dioxide, or hypromellose has lower differentiation unless bundled with regulatory and technical support.

Key Takeaways

• Mavyret uses a performance-oriented excipient system centered on vitamin E TPGS, propylene glycol monolaurate, copovidone, croscarmellose sodium, and sodium stearyl fumarate.
• The formulation is designed to manage hydrophobic drug substances while preserving immediate-release tablet performance.
• Oral pellets create the most differentiated commercial opportunity because they require specialized multiparticulate manufacturing and pediatric usability controls.
• Excipient suppliers can compete through pharmaceutical-grade consistency, impurity control, dual sourcing, and regulatory documentation.
• Generic development is possible through an ANDA pathway, but two active ingredients, formulation performance, patent claims, and dissolution requirements increase technical and legal complexity.
• Mavyret has no biosimilar pathway because it is a small-molecule drug.
• The current Orange Book and applicable patent records control the timing of Paragraph IV challenges and commercial launch.
• The highest-value commercial positions are integrated excipient systems, pediatric pellet manufacturing, analytical support, and global supply assurance.

FAQs

Can vitamin E TPGS be replaced in a generic Mavyret formulation?

Yes. A generic applicant may use a different solubilizer if the formulation meets FDA requirements and demonstrates equivalent quality, dissolution, and bioavailability. Replacement can increase development risk because the substitute may alter stability, food effects, tablet processing, or exposure.

Is Mavyret a complex generic drug product?

Mavyret is not a biologic, but its two-active fixed-dose formulation can be more challenging than a conventional single-ingredient immediate-release tablet. The combination of solubility-enhancing excipients and pediatric pellets creates additional development and manufacturing considerations.

What is the most valuable excipient opportunity linked to Mavyret?

The strongest opportunity is a validated solubilizer and binder platform combining vitamin E TPGS, a lipidic wetting agent, and copovidone with regulatory support. Pediatric pellet production is the strongest adjacent manufacturing opportunity.

Do Mavyret excipients create independent patent rights?

Excipients generally do not create patent rights merely because they are listed in the product. Patent exposure depends on active claims covering the composition, ratios, process, dosage form, solid state, or method of use.

Can a company commercialize Mavyret-like oral pellets before tablet patents expire?

Commercialization depends on the applicable patents, regulatory exclusivity, product claims, and jurisdiction. A pellet product may avoid some tablet-specific claims, but it can still implicate active-ingredient, combination, method-of-use, or manufacturing patents.

References

1. AbbVie Inc. (2024). Mavyret (glecaprevir and pibrentasvir) prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2017). FDA approves new treatment for hepatitis C virus. https://www.fda.gov

3. U.S. Food and Drug Administration. (2021). Mavyret oral pellets labeling and pediatric use information. https://www.accessdata.fda.gov

4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov

5. U.S. Food and Drug Administration. (2023). ANDA submissions: Pharmaceutical equivalence and bioequivalence requirements. https://www.fda.gov

6. European Association for the Study of the Liver. (2020). EASL recommendations on treatment of hepatitis C. Journal of Hepatology, 73(5), 1170-1218.